The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary antitumor activity of TRC102 in patients with advanced cancer who also receive Alimta.
Intravenous TRC102 is also being dosed to cancer patients in a Phase I clinical trial in combination with Temodar being conducted at University Hospitals Case Medical Center.
TRC102 is a small molecule that has been shown to reverse resistance to the chemotherapy agent Alimta in models of human cancer, by targeting the base excision repair pathway used to repair chemotherapy-induced DNA damage.